Europe Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombin

Europe Biopharmaceuticals Market Forecast to 2028-Regional Analysis- by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)

The Europe biopharmaceuticals market was valued at US$ 107.57 billion in 2022 and is expected to reach US$ 227.22 billion by 2028. It is estimated to register a CAGR of 13.3% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drive Europe Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceuticals companies to redirect resources to other important areas. Many biopharmaceuticals’ companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increase dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron for advancing the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. In November 2021, Abenza Limited, a biologics research partner, announced a collaboration with BiVictriX Therapeutics to manufacture the BiVictriX ADCs. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the Europe biopharmaceuticals market in the coming years.

Europe Biopharmaceuticals Market Overview

The Europe biopharmaceuticals market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Europe biopharmaceuticals market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, growing cancer incidences, and launch of innovative products by market players in the region. The emerging biopharmaceuticals industry in Europe results from an evolution of the traditional pharmaceutical industry. The industry has considered the recent advances in biotechnology developed on living cells and molecules that have resulted from key innovations in healthcare. The most specific area of biopharmaceuticals product development includes vaccines, blood components, hormones, antibodies, cell-based therapies, stem cells, gene therapy, or enzymes. In May 2019, the European Union approved 59 biosimilars, and many have been successfully commercialized. Most regions with strong clusters in the biopharmaceuticals industry are Belgium, Sweden, Germany, Norway, the UK, France, Italy, and Spain. Belgium can be identified as an important player in terms of biopharmaceuticals. Major Belgian pharmaceutical companies include Janssen Pharmaceutica, Solvay, UCB (Union Chimique Belge), GMED Healthcare, and subsidiaries such as BASF Antwerpen and GlaxoSmithKline Biologicals. The regions specializing in biopharmaceuticals perform well in many economic indicators due to high labor productivity. These regions also have numerous product and process, marketing, and organizational innovators, and they also score with high-tech employment. The growing population and chronic diseases are driving the market growth. Hence, based on the above factors, the Europe biopharmaceuticals market is expected to grow during the forecast period.

Exhibit: Europe Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Million)

Europe Biopharmaceuticals Market Segmentation

The Europe biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the Europe biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the Europe biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the Europe biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the Europe biopharmaceuticals market.

Based on country, the Europe biopharmaceuticals market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, Germany held the largest share of the Europe biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are among the leading companies operating in the Europe biopharmaceuticals market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe biopharmaceutical market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution